Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
Condition: Diffuse Large B-Cell Lymphoma Interventions: Drug: Acalabrutinib; Drug: Cyclophosphamide; Drug: Doxorubicin Hydrochloride; Drug: Lenalidomide; Drug: Prednisone; Biological: Rituximab; Biological: Tafasitamab; Drug: Vincristine Sponsor: M.D. Anderson Cancer Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Chemotherapy | Lymphoma | Prednisone | Research | Revlimid | Rituxan | Study